CA2483102C - Treatment and prevention of pulmonary conditions - Google Patents

Treatment and prevention of pulmonary conditions Download PDF

Info

Publication number
CA2483102C
CA2483102C CA2483102A CA2483102A CA2483102C CA 2483102 C CA2483102 C CA 2483102C CA 2483102 A CA2483102 A CA 2483102A CA 2483102 A CA2483102 A CA 2483102A CA 2483102 C CA2483102 C CA 2483102C
Authority
CA
Canada
Prior art keywords
leu
seq
gly
composition
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2483102A
Other languages
English (en)
French (fr)
Other versions
CA2483102A1 (en
Inventor
Charles G. Cochrane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA2483102A1 publication Critical patent/CA2483102A1/en
Application granted granted Critical
Publication of CA2483102C publication Critical patent/CA2483102C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2483102A 2002-04-25 2003-04-25 Treatment and prevention of pulmonary conditions Expired - Fee Related CA2483102C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37596802P 2002-04-25 2002-04-25
US60/375,968 2002-04-25
PCT/US2003/012731 WO2003090682A2 (en) 2002-04-25 2003-04-25 Treatment and prevention of pulmonary conditions

Publications (2)

Publication Number Publication Date
CA2483102A1 CA2483102A1 (en) 2003-11-06
CA2483102C true CA2483102C (en) 2013-06-18

Family

ID=29270737

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2483102A Expired - Fee Related CA2483102C (en) 2002-04-25 2003-04-25 Treatment and prevention of pulmonary conditions

Country Status (13)

Country Link
US (2) US7863241B2 (enExample)
EP (1) EP1558273B1 (enExample)
JP (2) JP4651946B2 (enExample)
KR (2) KR20110017465A (enExample)
CN (1) CN1838964A (enExample)
AT (1) ATE520411T1 (enExample)
AU (1) AU2003223718B2 (enExample)
CA (1) CA2483102C (enExample)
IL (2) IL164795A0 (enExample)
MX (1) MXPA04010560A (enExample)
NZ (1) NZ536796A (enExample)
WO (1) WO2003090682A2 (enExample)
ZA (1) ZA200408573B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090682A2 (en) 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2005055994A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
WO2005073246A2 (en) * 2004-01-20 2005-08-11 Discovery Laboratories, Inc. Method for preparing kl4 lung surfactant
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
WO2006014567A2 (en) 2004-07-08 2006-02-09 Pneumrx, Inc. Pleural effusion treatment device, method and material
EP1791555B1 (en) * 2004-09-10 2013-03-13 Pharmaorigin ApS Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
KR100770362B1 (ko) * 2004-12-30 2007-10-26 (주)두비엘 분무건조 고분자형 콜렉틴족 단백질 및 그의 제조방법
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
KR20080071116A (ko) * 2005-06-24 2008-08-01 드럭리큐어 에이피에스 기도에 영향을 미치는 염증 질환에 있어서 활성화 단백질c의 기도 투여법
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
CA2718130A1 (en) 2007-03-29 2008-10-09 National Jewish Health Surfactant lipids, compositions thereof, and uses thereof
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
ES2562806T3 (es) * 2007-06-05 2016-03-08 Paka Pulmonary Pharmaceuticals, Inc. Composiciones para administrar medicamentos en los pulmones, y usos de las mismas
EP2227085A4 (en) * 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
GB0724772D0 (en) * 2007-12-19 2008-01-30 Ucl Business Plc Carrier
CA2744940A1 (en) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2010087771A1 (en) 2009-01-30 2010-08-05 Alphabeta Ab Compound and method for treatment of alzheimer's disease
US8434479B2 (en) 2009-02-27 2013-05-07 Covidien Lp Flow rate compensation for transient thermal response of hot-wire anemometers
JP5622728B2 (ja) * 2009-08-06 2014-11-12 一般財団法人化学及血清療法研究所 咳嗽抑制効果を持つ血漿タンパク質
DK2308489T3 (da) * 2009-10-05 2014-03-24 Nutri Fit Gmbh & Co Kg Sammensætninger til anvendelse ved behandling eller forebyggelse af lungeskade, der fremkaldes af en stofskiftebelastning samt fremgangsmåder til forøgelse af pattedyrs fysiske kapacitet
TR201809898T4 (tr) * 2009-11-03 2018-07-23 Grifols Therapeutics Llc Alfa-1 protei̇naz i̇nhi̇bi̇törüne yöneli̇k bi̇leşi̇m, yöntem ve ki̇t.
JP5810091B2 (ja) 2009-11-24 2015-11-11 グリフオルス・セラピユーテイクス・インコーポレーテツドGrifols Therapeutics,Inc. 凍結乾燥方法、組成物、及びキット
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
CN105168135A (zh) 2010-03-12 2015-12-23 博格有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
CN101897720B (zh) * 2010-07-27 2015-09-09 北京华禧联合科技发展有限公司 一种治疗呼吸道疾病的药物组合物
US8623832B2 (en) * 2010-11-04 2014-01-07 The Board Of Regents Of The University Of Oklahoma Peptide compositions that bind TLR-4
US20130184202A1 (en) * 2011-02-08 2013-07-18 Changjiang Guo Peptide Inhibitors and Methods of Use Thereof
EP2694977B1 (en) 2011-04-05 2016-06-29 Alphabeta AB Amyloidosis target useful in methods of screening of compounds
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CN111110850A (zh) 2011-04-12 2020-05-08 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法
MX351781B (es) 2011-06-17 2017-10-30 Berg Llc Composiciones farmaceuticas inhalables.
US9089657B2 (en) 2011-10-31 2015-07-28 Covidien Lp Methods and systems for gating user initiated increases in oxygen concentration during ventilation
WO2013188016A2 (en) * 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
CN105745223A (zh) 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
WO2015039188A1 (en) * 2013-09-18 2015-03-26 James Cook University Anti-inflammatory proteins and methods of use
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
EP3185892B1 (en) * 2014-08-26 2020-02-12 Proteo Biotech AG Use of elafin for disorders associated with elastase independent increase in troponin
WO2016174600A1 (en) 2015-04-27 2016-11-03 Omniactive Health Technologies Limited Betacryptoxanthin compositions, processes for preparation and uses thereof
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione
WO2021207514A1 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CN109789193A (zh) * 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
EP3600374B1 (en) * 2017-03-31 2024-05-15 ENA Respiratory Pty Ltd Treatment of respiratory infection
JP7335263B2 (ja) * 2017-12-21 2023-08-29 キウィタス セラピューティクス,インコーポレイテッド 吸入のための界面活性剤製剤
EP3781123A1 (en) * 2018-04-17 2021-02-24 Lamellar Biomedical Limited Antifibrotic composition
MX2021001877A (es) * 2018-08-17 2021-07-15 Univ Pennsylvania Composiciones y métodos para el tratamiento de lesión pulmonar aguda.
KR20210082186A (ko) 2018-10-19 2021-07-02 오하이오 스테이트 이노베이션 파운데이션 폐 염증 요법을 위한 나노담체
CN120285204A (zh) * 2018-10-23 2025-07-11 G·E·霍格 用于治疗肺的组合物和方法
US12220400B2 (en) * 2018-10-30 2025-02-11 Amilyfe, Llc Amino acid compositions and methods for treating cystic fibrosis
EP4007751A4 (en) * 2019-08-01 2023-07-05 Serplus Technology LLC OXIDATION RESISTANT SERPINES
KR102276935B1 (ko) * 2020-02-06 2021-07-12 한양대학교 산학협력단 신규한 비올라크산틴 고생산 클로렐라 불가리스 균주 및 이로부터 비올라크산틴을 생산하는 방법
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN120000688B (zh) * 2025-04-16 2025-08-05 山东杰凯生物科技有限公司 基于干细胞外囊泡的雾化吸入组合物及其制备方法、应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144224A (en) * 1981-03-02 1982-09-06 Mochida Pharmaceut Co Ltd Remedy for respiratory dieseases
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
DE69033745T2 (de) * 1989-07-11 2002-02-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Oberflächenaktive zusammensetzungen und verfahren
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
EP0652894B1 (en) * 1992-07-31 1997-09-03 Merrell Pharmaceuticals Inc. Synthetic peptide lung surfactants having covalently bonded antioxidants
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5301644A (en) * 1993-06-16 1994-04-12 Kohler Co. Fuel shut-off mechanism for internal combustion engines
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JP3721538B2 (ja) * 1994-06-02 2005-11-30 メレル ファーマスーティカルズ インコーポレイテッド エラスターゼのパーフルオロアルキルケトン阻害剤およびそれらを製造する方法
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5878912A (en) * 1995-12-26 1999-03-09 Stein; Myron Duct disinfecting method and apparatus
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AU5806898A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes and compositions for spray drying hydrophobic drugs in organic solventsuspensions of hydrophilic excipients
US6051257A (en) * 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
JP3796340B2 (ja) * 1997-11-18 2006-07-12 株式会社ノエビア セリンプロテアーゼ阻害剤
JPH11147832A (ja) * 1997-11-18 1999-06-02 Noevir Co Ltd 好中球エラスターゼ阻害剤
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
EP1216052A1 (en) * 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
JP2003522133A (ja) * 1999-12-28 2003-07-22 ノバルティス アクチエンゲゼルシャフト 持続性導入遺伝子発現を実現する方法
WO2001049315A1 (en) * 2000-01-06 2001-07-12 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
WO2003090682A2 (en) 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US6819898B2 (en) * 2002-11-22 2004-11-16 Kabushiki Kaisha Toshiba Image forming apparatus including stopping member and backstop member to stop rotation of revolver type developing unit

Also Published As

Publication number Publication date
KR20110017465A (ko) 2011-02-21
US20050070477A1 (en) 2005-03-31
AU2003223718C1 (en) 2003-11-10
EP1558273B1 (en) 2011-08-17
CA2483102A1 (en) 2003-11-06
ATE520411T1 (de) 2011-09-15
AU2003223718B2 (en) 2007-08-16
US7863241B2 (en) 2011-01-04
WO2003090682A3 (en) 2004-09-16
AU2003223718A1 (en) 2003-11-10
ZA200408573B (en) 2006-03-29
IL164795A (en) 2011-02-28
JP2011001383A (ja) 2011-01-06
CN1838964A (zh) 2006-09-27
JP2005529885A (ja) 2005-10-06
MXPA04010560A (es) 2005-08-15
KR20050019073A (ko) 2005-02-28
IL164795A0 (en) 2005-12-18
EP1558273A4 (en) 2008-07-16
NZ536796A (en) 2007-03-30
WO2003090682A2 (en) 2003-11-06
JP4651946B2 (ja) 2011-03-16
EP1558273A2 (en) 2005-08-03
KR101036058B1 (ko) 2011-05-19
US20120189602A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
CA2483102C (en) Treatment and prevention of pulmonary conditions
JP2005529885A5 (enExample)
EP1005485B1 (en) Therapeutic pulmonary lavage with diluted surfactants
JP5405307B2 (ja) 改善された性質を有する再構成サーファクタント
JP2013177422A (ja) サーファクタント処置療法
US20070129297A1 (en) Treatment and prevention of asthma
WO2007005672A2 (en) Treatment and prevention of respiratory diseases and conditions
EP1140150B1 (en) Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor
WO2015061412A1 (en) Methods and compositions for promoting bronchioli dilatation
US20070140979A1 (en) Method for accelerating the rate of mucociliary clearance
MXPA00003231A (en) Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
HK1109078B (en) Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180425